Hosted on MSN1mon
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerBluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback